News

According to Optimer, Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium

As a result, McKesson can now provide customers with the same distribution service for plasma and biologics products that they have come to rely upon for pharmaceuticals. McKesson

As general counsel, Mr Zachara will lead Cambrex’s legal function, overseeing the traditional legal activities related to commercial transactions, intellectual property, regulatory compliance, environmental, litigation, employment, corporate governance,

Prior to his recent retirement from Bristol-Myers, Dr Smyth led oncology medical affairs in the US, including the US life-cycle development of paclitaxel, carboplatin and ifosfamide. Prior to

In this role, Mr Cuneo is responsible for coordinating Mylan’s global business development and strategic efforts in close alignment with the company’s executive leadership team. Mr Cuneo joins

Mr Myslinski has been a Johnson & Johnson executive since 2002 where his responsibilities have included building a new, world-wide evidence based medicine function for the ortho-clinical diagnostics

The terms of the licensing agreement provide for payments to Rosetta, either as milestones or R&D funding, as well as royalty payments on net sales in the US.

India-based Glenmark Pharmaceuticals has reported that its candidate for neuropathic pain, osteoarthritis and other inflammatory pain disorders – GRC 10693, has successfully completed Phase I trials in Europe.

Suven Life Sciences, an Indian drug discovery and development company, has completed its Phase I multiple ascending dose study of SUVN-502 in healthy volunteers. SUVN-502 is reported to